Related Experiment Video
Updated: Sep 30, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond
1Merck Research Laboratories, RY80W107, 126 East Lincoln Avenue, Rahway 07065, NJ, USA. Francis_Dumont@merck.com
Insights
CAMPATH (alemtuzumab) is a monoclonal antibody approved for chronic lymphocytic leukemia (CLL). It effectively targets CD52 on malignant lymphocytes while sparing stem cells, showing efficacy in chemotherapy-refractory CLL.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Campath (alemtuzumab) is a humanized monoclonal antibody targeting CD52.
- CD52 is highly expressed on lymphocytes and lymphoid malignancies but not hematopoietic progenitor cells.
- Campath is approved for chronic lymphocytic leukemia (CLL) treatment in the USA and Europe.
Purpose of the Study:
- To evaluate the efficacy and safety of Campath in treating chronic lymphocytic leukemia (CLL).
- To highlight Campath's role in managing chemotherapy-refractory CLL.
- To discuss Campath's applications in T-cell prolymphocytic leukemia and graft-versus-host disease prevention.
Main Methods:
- Campath (alemtuzumab) administration.
- Assessment of efficacy in chronic lymphocytic leukemia (CLL) and other lymphoid malignancies.
- Evaluation of toxicity profile and safety.
Main Results:
- Campath demonstrates effectiveness against chronic lymphocytic leukemia (CLL) refractory to chemotherapy.
- An acceptable toxicity profile was observed.
- Campath is also active in T-cell prolymphocytic leukemia and prevents graft-versus-host disease.
Conclusions:
- Campath (alemtuzumab) is an effective treatment for chronic lymphocytic leukemia (CLL), particularly in refractory cases.
- Its targeted mechanism spares hematopoietic progenitor cells, contributing to an acceptable safety profile.
- Campath has broader applications in hematologic malignancies and transplantation immunology.
Abstract:
CAMPATH (CAMPATH-1H, alemtuzumab, MabCAMPATH), is a lymphocyte-depleting humanized monoclonal antibody that was recently approved in the USA and Europe for the treatment of chronic lymphocytic leukemia (CLL). It targets CD52--a small glycosylphosphatidylinositol-anchored glycoprotein that is highly expressed on normal T- and B-lymphocytes and on a large proportion of lymphoid cell malignancies--but not on hematopoietic progenitor cells. CAMPATH was shown to be effective against CLL refractory to chemotherapy with an acceptable toxicity profile. CAMPATH is also active against T-cell prolymphocytic leukemia and has been extensively used to prevent graft-versus-host disease associated with bone marrow transplantation. CAMPATH is owned by ILEX Pharmaceuticals LP and distributed by Schering AG and its US affiliate Berlex Laboratories.
